# A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

> **NCT06015048** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 364 (estimated)

## Conditions studied

- HER2-expressing Advanced Solid Tumors

## Interventions

- **DRUG:** SHR-A1811 combined with Pyrotinib.
- **DRUG:** SHR-A1811 combined with other antitumor therapies

## Key facts

- **NCT ID:** NCT06015048
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-11
- **Primary completion:** 2026-11
- **Final completion:** 2026-12-29
- **Target enrollment:** 364 (ESTIMATED)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015048, "A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06015048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*